Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Selin CebeciDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.
Zeliha BirsinDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.ORCID 0000-0002-2645-0785
Seda Jeral EvinçDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.ORCID 0000-0002-6594-1712
Hamza AbbasovDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.ORCID 0000-0003-1227-9996
Vali AliyevDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.
Emir ÇermeDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.
Ebru ÇiçekDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.
Süheyla AtakDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.
Murat GünaltılıDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.ORCID 0000-0001-6116-3936
Murad GuliyevDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.ORCID 0000-0002-2981-8098
Nebi Serkan DemirciDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.
Lebriz Uslu BeşliDepartment of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.ORCID 0000-0003-1868-3957
Özkan AlanDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34320 Istanbul, Türkiye.ORCID 0000-0002-6635-2012
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
body compositionCDK 4/6 inhibitorsmetastatic breast cancerPET/CTprogression-free survivalsarcopeniaskeletal muscle index
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Prognostic Impact of PET/CT-Derived Sarcopenia in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors. · full record | OpenQuestion